The NLR family of proteins is recognized for its roles in inflammasome-mediated responses to both pathogen-associated molecular patterns and damage-associated molecular patterns 1 . However, several NLR proteins, including NLRX1, NLRC3, NLRC5 and NLRP12, act as negative regulators of innate immunity with the ability to check type I interferon responses or NF-κB-induced pro-inflammatory cytokines [2] [3] [4] [5] . NLRX1 is distinguished from other members of the NLR family by its localization to mitochondria, where it interacts with MAVS through its unique amino-terminal X domain and nucleotidebinding-oligomerization domain, sequesters MAVS and suppresses virus-induced interferon responses mediated by the pathogen sensor RIG-I 6 . NLRX1 also negatively regulates lipopolysaccharide-induced activation of NF-κB, interacting with the adaptor TRAF6 in unstimulated cells and being recruited to the NEMO-IKK signaling complex following lipopolysaccharide stimulation via its leucine-rich-repeat domain 3 . Deletion or functional knockdown of NLRX1 results in heightened interferon responses to the synthetic RNA duplex and Toll-like receptor 3 (TLR3) agonist poly(I:C) or RNA viruses, as well as increased inflammatory responses 3, 6, 7 . Acting like a Swiss Army knife, NLRX1 also interacts with STING through its nucleotidebinding-oligomerization domain and thereby inhibits interferon responses to DNA viruses mediated through the cGAS-cGAMP signaling pathway 8 . Abundant evidence thus supports the concept that NLRX1 functions as a checkpoint inhibitor of early innate immune responses to both DNA viruses and RNA viruses.
However, not all studies have shown that NLRX1 exerts negative regulatory effects on innate immune responses to viruses. Sendai virus (SeV)-induced RIG-I-and MAVS-dependent phosphorylation of IRF3 and production of interferon-β (IFN-β) and the chemokine IP10 (CXCL10) are reported to be unchanged in Nlrx1 −/− mouse embryonic fibroblasts (MEFs), relative to that of wild-type MEFs, as are cytokine IL-6 and IFN-β responses to poly(I:C) 9 . Although inflammatory responses to infection with influenza virus are enhanced in the lungs of Nlrx1 −/− mice relative to those in the lungs of of wild-type mice 7 , their macrophage-mediated interferon responses are impaired, secondary to enhanced apoptosis 10 . Also, rather than inhibiting NF-κB signaling, overexpression of NLRX1 enhances such signaling by amplifying the production of reactive oxygen species in response to several stimuli 11 . Such findings are puzzling given that the preponderance of evidence favors a negative regulatory role for NLRX1. While they might reflect different experimental conditions, they have fueled controversy about the regulatory role of NLRX1.
NLRX1 is unique among the nucleotide-binding-domain and leucine-rich-repeat (NLR) proteins in its mitochondrial localization and ability to negatively regulate antiviral innate immunity dependent on the adaptors MAVS and STING. However, some studies have suggested a positive regulatory role for NLRX1 in inducing antiviral responses. We found that NLRX1 exerted opposing regulatory effects on viral activation of the transcription factors IRF1 and IRF3, which might potentially explain such contradictory results. Whereas NLRX1 suppressed MAVS-mediated activation of IRF3, it conversely facilitated virus-induced increases in IRF1 expression and thereby enhanced control of viral infection. NLRX1 had a minimal effect on the transcription of IRF1 mediated by the transcription factor NF-kB and regulated the abundance of IRF1 post-transcriptionally by preventing translational shutdown mediated by the double-stranded RNA (dsRNA)-activated kinase PKR and thereby allowed virus-induced increases in the abundance of IRF1 protein.
A r t i c l e s
Here we sought to understand how NLRX1 influences innate immune responses to viral infection of human hepatocytes. Hepatocytes are targeted for infection by several medically important viruses, including hepatitis A virus (HAV) and hepatitis C virus (HCV), which are RNA viruses that cause inflammatory diseases of the liver 12 . We found that NLRX1 competed with dsRNA-activated PKR for binding to viral RNA and that it promoted early innate immune antiviral responses by protecting NF-κB-driven increases in the expression of IRF1 from translational suppression mediated by PKR. Hepatocytes deficient in NLRX1 expression had diminished accumulation of IRF1 but more formation of IRF3 dimers in response to viral infection, relative to that of hepatocytes sufficient in NLRX1; this revealed opposing actions of NLRX1 on key signaling pathways. Our data identify a previously unknown and sophisticated regulation of early innate immune responses by NLRX1 that, overall, promotes immediate antiviral defense in hepatocytes.
RESULTS

NLRX1 is a positive immunoregulator in hepatocytes
To determine how NLRX1 influences antiviral responses in hepatocytes, we used CRISPR-Cas9 gene editing to eliminate its expression in PH5CH8 cells, which are T antigen-transformed primary human hepatocytes with functional signaling via RIG-I and TLR3 (refs. 13,14) . NLRX1 expression was detected in PH5CH8 cells transduced with a nontargeting single guide RNA (sgRNA) with a scrambled sequence (called 'control PH5CH8 cells' throughout) but not in either of two independent PH5CH8 cell lines (NLRX1-T2 and NLRX1-T3) transduced with different NLRX1-specific sgRNAs ( Fig. 1a and Supplementary Table 1 ). We initiated HCV replication in these cells by electroporating synthetic viral RNA and the duplex microRNA miR-122, an essential HCV host factor that PH5CH8 cells lack 15 , together into the cells. We demonstrated that subsequent increases in viral RNA were due to true viral replication because they were blocked by a direct-acting antiviral inhibitor ( Fig. 1b) . We also infected the cells directly with HAV 16 . Replication of each virus was enhanced in NLRX1-deficient (NLRX1-T2 and NLRX1-T3) cells relative to that of control PH5CH8 cells ( Fig. 1b) . We similarly assessed HAV replication in primary human fetal hepatoblasts (HFHs). Partial depletion of NLRX1 via RNA-mediated interference boosted viral replication in cells from two donors ( Fig. 1c) , which confirmed an antiviral role for NLRX1 in human liver cells.
Although innate immune responses restrict infection with HAV or HCV in PH5CH8 cells, it is difficult to document the induction of antiviral cytokines in these cells following viral challenge. We thus employed a classic agonist of RIG-I signaling, SeV, to define the effect of NLRX1 deficiency on cytokine responses. We observed significantly lower IFNB1, IFNL1, IL1B and IL6 mRNA responses early (at 3 h) in SeV-infected NLRX1-deficient (NLRX1-T2 and NLRX1-T3) cells than in SeV-infected control PH5CH8 cells ( Fig. 1d) . This effect was no longer evident at 8 h, by which time these responses had substantially subsided ( Supplementary Fig. 1a ). NLRX1 deficiency also impaired the accumulation of IL1B and IL6 mRNA, but not that of IFNB1 mRNA, in response to poly(I:C) added to the medium (Fig. 1e) . NLRX1 deficiency consistently reduced the amount of IL-6 protein induced in response to stimulation with SeV or poly(I:C) ( Fig. 1f) . Likewise, small interfering RNA (siRNA)-mediated depletion of NLRX1 significantly impaired the increase in IL-6 protein induced by infection of primary HFHs with SeV ( Fig. 1g) . Neither HAV nor HCV replicates in mouse cells, but we observed a reduction of approximate fourfold in the early (3-hour) intrahepatic Ifnb and Il6 mRNA responses to synthetic HAV RNA administered intravenously to Nlrx1 −/− mice, relative to the responses in their wildtype counterparts (Fig. 1h) .
Supplementing PH5CH8 cells with the antioxidant NAC (N-acetyll-cysteine) did not abolish the positive effect of NLRX1 deficiency on the replication of an HCV reporter virus, nor did treating cells with an inhibitor of endoplasmic reticulum stress (TUDCA) or autophagy (3-MA) ( Supplementary Fig. 1b ). Thus, the increased HCV replication in NLRX1-deficient cells was probably not due to diminished production of reactive oxygen species 11, 17 or to the influence of NLRX1 depletion on autophagy or the response to endoplasmic reticulum stress 18, 19 .
To ascertain whether the proviral effect of NLRX1 deficiency resulted from a reduction in early innate immune response, we designed a Transwell assay for soluble antiviral factors ( Supplementary  Fig. 1c ). We assessed replication of an HCV reporter virus in indicator cells separated by a permeable membrane from NLRX1-deficient cells or control PH5CH8 cells, each stimulated by replication-competent HCV RNA, and found greater replication of the reporter virus in indicator cells exposed to NLRX1-deficient cells than in those exposed to control PH5CH8 cells ( Supplementary Fig. 1c ). Inhibition of JAK-STAT signaling with ruxolitinib (an inhibitor of JAK1 and JAK2) or tofacitinib (an inhibitor of JAK3) also substantially reduced the difference in HCV replication in NLRX1-T3 cells relative to that in control PH5CH8 cells ( Supplementary Fig. 1d ), consistent with the suppression of viral replication by cytokine responses involving JAK signaling. Depleting cells of NLRX1 had no effect on the replication of HAV or HCV in RIG-I-deficient Huh-7.5 human hepatoma cells 20 (Supplementary Fig. 1e ) or in MAVS-deficient PH5CH8 cells ( Supplementary Fig. 1f ). Collectively, these results defined NLRX1 as a positive regulator of soluble RIG-I-and MAVS-mediated antiviral responses in human hepatocytes.
NLRX1 regulates IRF3 and IRF1 responses differentially
We carried out a series of dual-luciferase-promoter assays to determine if NLRX1 directly regulated the transcription of cytokine-encoding genes. NLRX1 deficiency had little effect on the basal activity of the NF-κB-responsive promoter PRDII but modestly reduced its activation by SeV ( Fig. 2a) . Consistent with that, overexpression of NLRX1 enhanced the activation of PRDII triggered by SeV ( Fig. 2a) . In contrast, NLRX1 deficiency minimally affected activation of the IFNB1 promoter and had no effect on the IRF3-responsive promoter 4*PRD(I/III) ( Supplementary Fig. 2a,b ). We also assessed the effect of NLRX1 deficiency on the stability of IL6 mRNA, as IL-6 expression is regulated in part through 3′ untranslated region (UTR) sequences programmed for rapid mRNA turnover 21 . NLRX1 deficiency had no effect on IL6 mRNA decay in cells treated with actinomycin D (Supplementary Fig. 2c ), nor did overexpression of NLRX1 alter luciferase expression from mRNA transcripts containing the IL6 3′ UTR (Supplementary Fig. 2d ). In aggregate, these data suggested that NLRX1 had a positive but limited effect on the activation of NF-κB-responsive promoters by SeV and had no influence on the stability of IL6 mRNA.
To more directly investigate the influence of NLRX1 deficiency on the activation of NF-κB, we assessed SeV-induced signaling via the NF-κB subunit RELA (p65). NLRX1 deficiency minimally affected phosphorylation of the inhibitory cytoplasmic NF-κB chaperone NFKBIA (IκBα) or RELA in SeV-infected PH5CH8 cells ( Supplementary Fig. 2e ). An electrophoretic mobility-shift assay with an NF-κB probe revealed a significant but quantitatively small decrease in the intensity of SeV-induced band shifts in NLRX1deficient (NLRX1-T2 and NLRX1-T3) PH5CH8 cells relative to that A r t i c l e s A r t i c l e s in control PH5CH8 cells ( Fig. 2b) . We concluded from these data that NLRX1 deficiency minimally suppressed SeV-induced NF-κB signaling in PH5CH8 cells and that this subtle impairment of NF-κB signaling probably did not explain the marked reductions we observed in cytokine expression.
To further test our hypothesis, we assessed how depleting RELA influenced IL-6 production after SeV infection and the modulation of IL-6 expression by NLRX1 in PH5CH8 cells. As anticipated, RELA deficiency caused a large decrease in the SeV-induced expression of IL-6 protein ( Fig. 2c) . Notably, however, eliminating NLRX1
Shifted probe
Free probe A r t i c l e s expression resulted in a further reduction in IL-6 production in RELA-deficient cells (Fig. 2c) . Thus, the negative effect of NLRX1 deficiency on the IL-6 response that we observed in RELA-replete cells was preserved in RELA-deficient cells. Collectively, these results indicated that NLRX1 regulated IL-6 production downstream and independently of NF-κB. Although our data showed that IL-6 was strongly regulated by NF-κB in PH5CH8 cells ( Fig. 2c) , CRISPR-Cas9-mediated depletion of BMDMs WT Nlrx1 A r t i c l e s either of two members of the IRF family of transcription factors, IRF1 and IRF3, suppressed early (3-hour) IL1B and IL6 mRNA and IL-6 protein responses to SeV (Supplementary Fig. 2f-h) . Because IRF1 and IRF3 regulate the induction of IFNB1 and IFNL1 transcripts in human hepatoma cells 22 , we assessed the effect of NLRX1 deficiency on IRF3 and IRF1 responses in PH5CH8 cells. IRF3 is constitutively expressed and is activated by phosphorylation, which leads to its dimerization and cytoplasmic-nuclear translocation 23 . NLRX1 deficiency significantly enhanced this response and led to an increase in the SeV-induced formation of IRF3 dimers (Fig. 2d) . Basal expression of IRF1 protein was low in mock-infected cells but was substantially induced by infection with SeV ( Fig. 2e) . In contrast to the enhancement observed in the activation of IRF3, NLRX1 deficiency significantly reduced the SeV-triggered increases in the abundance of IRF1 ( Fig. 2e) . Reconstituting NLRX1 expression in NLRX1-T3 cells with recombinant lentivirus reversed both of those changes (Fig. 2f) . Collectively, these data revealed that NLRX1 regulated SeV-induced IRF3 signaling and IRF1 signaling in hepatocytes differentially, suppressing the activation of IRF3 but enhancing increases in IRF1 expression.
NLRX1's promotion of IRF1 dominates in hepatocytes
Because NLRX1 deficiency suppresses innate immunological control of viral replication in hepatocytes, we reasoned that the positive regulation of IRF1 by NLRX1, rather than its negative regulation of IRF3, probably dominates cytokine responses in hepatocytes. To test our hypothesis, we depleted IRF1-and IRF3-deficient PH5CH8 cells of NLRX1 expression and assessed responses to SeV challenge in the resulting NLRX1-IRF3 or NLRX1-IRF1 doubly deficient cells. In IRF3-deficient cells, the IRF1 and IL-6 protein responses to infection with SeV were suppressed and HAV replication was enhanced by depletion of NLRX1 (Fig. 3a) . Thus, the effect of NLRX1 depletion in IRF3-deficient PH5CH8 cells was similar to that in unmodified PH5CH8 cells. In contrast, depleting IRF1-deficient cells of NLRX1 enhanced the formation of IRF3 dimers (as in IRF1-replete cells) but enhanced the SeV-induced production of IL-6 and also suppressed HAV replication (Fig. 3b) . Thus, the effects of NLRX1 depletion on cytokine expression and viral replication were reversed in IRF1deficient cells, which suggested that the NLRX1-IRF1 signaling axis is dominant in hepatocytes. Consistent with that conclusion, the reduced production of IL-6 in SeV-infected HFHs depleted of NLRX1 ( Fig. 1g) was accompanied by a reduction in the accumulation of IRF1 protein (Fig. 3c) .
Most reports suggest that rather than enhancing such responses, NLRX1 suppresses, early innate immune responses in bone-marrow-derived macrophages (BMDMs) and primary MEFs [6] [7] [8] . Thus, we sought to determine whether IRF1 signaling was negatively or positively regulated by NLRX1 in these cell types. Consistent with a suppressive effect on innate immunity, we found that loss of NLRX1 enhanced the SeV-mediated Ifnb, Tnf and Il6 mRNA responses in mouse BMDMs and MEFs (Fig. 3d) . Despite that, NLRX1 deficiency reduced the SeV-triggered increase in the abundance of IRF1 protein in both cell types (Fig. 3e) . Thus, the positive regulation of IRF1 signaling by NLRX1 was not specific to hepatocytes or human cells. The finding that cytokine responses were enhanced, while IRF1 induction was decreased, in BMDMs and MEFs depleted of NLRX1 indicated that IRF1 did not have a dominant role in determining cytokine responses in these cells. Thus, the ultimate effect of NLRX1 on early antiviral responses was determined by whether IRF1 or IRF3 dominated in driving the response.
NLRX1 enhances IRF1 protein synthesis in infected cells IRF1 is the 'founding member' of the IRF family, and its expression is induced rapidly by viral infection 24, 25 . However, the mechanisms that mediate this response are poorly understood. Given its role in initiating IRF3-directed responses to SeV in hepatocytes 20 , we reasoned that RIG-I and its adaptor MAVS might mediate the IRF1 response. Consistent with that, depleting cells of MAVS significantly suppressed both IRF3 responses and IRF1 responses to SeV infection in PH5CH8 cells (Supplementary Fig. 3a) . The loss of SeV-induced dimerization of IRF3 and expression of IRF1 protein was not reversed by additional depletion of NLRX1 in MAVS-deficient PH5CH8 cells (Supplementary Fig. 3a) .
Consistent with published studies showing that increased IRF1 transcription drives the IRF1 protein response to viral infection 25 , globally inhibiting transcription with actinomycin D completely abolished the IRF1 protein response to SeV (Supplementary Fig. 3b ). To better understand how NLRX1 might regulate this IRF1 response, we assessed the roles of IRF3 and NF-κB. Notably, depleting cells of IRF3 had no effect on either the transcription of IRF1 or the expression of IRF1 protein (Supplementary Fig. 3c ). In contrast, depleting cells of RELA significantly suppressed both the transcription of IRF1 and the increase in expression of IRF1 protein in response to SeV in PH5CH8 cells (Supplementary Fig. 3d ). siRNA-mediated silencing of NFKB1, which encodes the NF-κB subunit p50, modestly diminished the IRF1 protein response to SeV infection, and in combination with RELA deficiency, it substantially reduced the SeV-induced abundance of IRF1 transcripts (Supplementary Fig. 3e,f) . Collectively, these data demonstrated that the immediate (3-hour) increase in the expression of IRF1 protein in response to infection with SeV was driven by signaling via MAVS and NF-κB in PH5CH8 cells.
Notably, although NLRX1 deficiency modestly enhanced the SeV-induced abundance of IRF3 transcripts (Supplementary Fig. 4a) , it had no effect on either the abundance of IRF1 transcripts (Fig. 4a) or the stability of IRF1 mRNA (Fig. 4b) . These data were in agreement with our earlier observations indicating an only modest impairment of NF-κB signaling in NLRX1-deficient cells (Fig. 2b) and collectively indicated that NLRX1 regulated IRF1 expression post-transcriptionally. To gain insight into whether this negative regulation of the IRF1 response was due to enhanced degradation of IRF1 or reduced synthesis of IRF1 protein, we globally inhibited protein synthesis in SeV-infected cells with cycloheximide and monitored the subsequent decay of IRF1 protein. Despite the greater initial abundance of IRF1 in control PH5CH8 cells than in NLRX1-T3 cells, the half-life (stability) of IRF1 protein in NLRX1-T3 cells was indistinguishable from that in control PH5CH8 cells ( Fig. 4c and Supplementary  Fig. 4b) . Collectively, these data suggested that the reduced abundance of IRF1 protein in NLRX1-deficient cells resulted from impaired translation of IRF1 mRNA. Consistent with that, globally blocking protein synthesis with puromycin completely abolished the effect of NLRX1 deficiency on the IRF1 response to infection with SeV (Supplementary Fig. 4c) .
To determine how NLRX1 might influence protein synthesis, we measured the incorporation of [ 35 Fig. 4d ). However, whereas infection with SeV induced a significant, quantitative increase in protein synthesis in control PH5CH8 cells, it had a much smaller, nonsignificant effect on NLRX1-T3 cells (Fig. 4d) . The absence of any novel protein bands incorporating [ 35 S]-Met-Cys that were not A r t i c l e s Supplementary Fig. 4b ) at various times (horizontal axis) after treatment with cycloheximide (CHX). (d) Nascent protein synthesis in control PH5CH8 cells and NLRX1-T3 cells (key) mock infected (0) or infected for 3 h with SeV, assessed as the incorporation of [ 35 S]-Met-Cys into cellular proteins (precipitated from cells by trichloroacetic acid), relative to that in uninfected control PH5CH8 cells, set as 100% (immunoblot analysis, Supplementary Fig. 4d ). A r t i c l e s present in the lysates of uninfected cells (Supplementary Fig. 4d ) indicated that this increase was due to enhanced cellular protein synthesis, not viral protein synthesis. As an independent measure of protein synthesis, we pulse-labeled NLRX1-T3 cells with a low concentration of puromycin and used confocal microscopy to monitor its incorporation into nascent protein at a single-cell level (Fig. 4e) . Infection with SeV induced an increase in nascent protein synthesis in a large proportion of control PH5CH8 cells but not in NLRX1-T3 cells (Fig. 4e) . We obtained similar results with NLRX1-T2 cells, at both a whole-cell-culture level and a single-cell level of analysis (Supplementary Fig. 4e) , which excluded the possibility that this reflected an off-target effect of the sgRNA used to create the T3  T3  T3  T3   3  0  3  0  3   IRF1   IRF3 A r t i c l e s NLRX1-T3 cells. siRNA-mediated depletion of NLRX1 expression in primary HFHs also substantially suppressed the SeV-induced increases in nascent protein synthesis (Supplementary Fig. 4f ).
S]-labeled methionine and cysteine ([ 35 S]-Met-Cys) into protein. Protein synthesis in NLRX1-T3 cells was qualitatively similar to that in control PH5CH8 cells, both before infection with SeV and after such infection (Supplementary
Although NLRX1 exerted distinctly different regulatory effects on SeV-induced cytokine expression in MEFs relative to that human hepatocytes, depleting cells of NLRX1 expression reduced the SeV-induced increase in the abundance of IRF1 in both cell types ( Figs. 2e and 3e) . Consistent with that finding, the incorporation of puromycin into nascent protein was also significantly lower in SeVinfected MEFs from Nlrx1 −/− mice than in those from wild-type mice (Supplementary Fig. 4g) . Thus, the negative effect of NLRX1 deficiency on protein synthesis in virus-infected cells was not limited to human hepatocytes.
To directly characterize the effect of NLRX1 deficiency on the translation of mRNA by ribosomes, we used sucrose-density-gradient fractionation to profile polysome formation following the infection of NLRX1-T3 cells or control PH5CH8 cells with SeV (Fig. 4f) . The deletion of NLRX1 resulted in a significant shift in the gradient distribution of IRF1, IRF3 and ACTB mRNA from SeV-infected cells, with a significantly lower proportion of each mRNA associated with translationally active polysomes (fractions 7-13) (Fig. 4g) . Moreover, the formation of translationally competent 80S ribosomes was lower in SeV-infected NLRX1-T3 cells than in SeV-infected control PH5CH8 cells, as shown by the much lower ratio of 80S to the 40S subunit in SeV-infected NLRX1-T3 cells than in SeV-infected control PH5CH8 cells ( Fig. 4h and Supplementary Fig. 4h) ; this suggested a defect in initiation of translation. Collectively, these three separate measures of protein synthesis-incorporation of [ 35 S]-Met-Cys, puromycin labeling and polysome profiling-indicated that the translation of mRNA was globally suppressed by the absence of NLRX1 expression in SeV-infected cells.
NLRX1 limits PKR-mediated global translational shutdown
The dsRNA-activated kinase PKR is triggered by viral infection to phosphorylate the translation-initiation factor eIF2α and thereby globally shuts down host-cell translation 26 . To ascertain whether NLRX1 influences that PKR response, we characterized the activation of PKR in NLRX1-deficient cells. NLRX1 deficiency enhanced the SeV-induced autophosphorylation of PKR, as well as phosphorylation of the PKR substrate eIF2α ( Fig. 5a and Supplementary Fig. 5a ).
To determine whether NLRX1 facilitated virus-induced increases in IRF1 protein synthesis by suppressing PKR responses, we generated PH5CH8 cells doubly deficient in NLRX1 and PKR (Fig. 5b) . The negative effect of the deletion of NLRX1 on SeV-triggered IRF1 responses was completely abolished by PKR deficiency (Fig. 5c ). PKR deficiency also fully restored the SeV-triggered immediate IL-6 protein response (Fig. 5d) and abolished the beneficial effect conferred on HAV replication by NLRX1 deficiency (Fig. 5e) . We also assessed the effect of SeV infection on nascent protein synthesis in the cells doubly deficient in NLRX1 and PKR. In contrast to the lack of increase in the incorporation of [ 35 S]-Met-Cys or puromycin into NLRX1deficient cells, relative to that in control PH5CH8 cells (Fig. 4d,e ), protein synthesis increased over time in response to SeV infection in both cells doubly deficient in NLRX1 and PKR and those deficient in PKR alone ( Fig. 5f and Supplementary Fig. 5b) .
To explore the mechanism by which NLRX1 suppressed PKR responses, we investigated whether NLRX1 physically interacted with PKR in hepatocytes. However, no co-immunoprecipitation of PKR protein with either endogenous NLRX1 or overexpressed NLRX1 was detectable in PH5CH8 cells (Supplementary Fig. 5c,d) . Since NLRX1 binds both viral RNA and poly(I:C), a common surrogate for viral dsRNA 27, 28 , we reasoned that NLRX1 might suppress the activation of PKR by competing for viral RNA in infected cells. To test our hypothesis, we first confirmed that NLRX1 bound HAV genomic RNA, which is known to have extensive secondary structure 29 , in bidirectional precipitation assays (Fig. 5g) . Next, we designed a cellfree competition assay in which lysates of NLRX1-deficient cells were used as a source of PKR, supplemented with purified recombinant NLRX1 protein and biotin-tagged HAV RNA or poly(I:C). The addition of increasing amounts of recombinant NLRX1 protein led to a progressive reduction in the binding of PKR to viral RNA or poly(I:C) ( Fig. 5h) , which indicated that NLRX1 competed with PKR for binding to viral RNA. Together these results demonstrated that NLRX1 suppressed the activation of PKR, in part by competitively binding viral RNA, and thereby prevented the PKR-mediated translational shutdown that would otherwise attenuate IRF1-mediated antiviral responses (Supplementary Fig. 5e ).
DISCUSSION
Although some studies have reported NLRX1 to be a negative regulator of innate immunity 3, 6, 8, 30 , others have not confirmed that 9, 31 or have even suggested that NLRX1 enhances antiviral responses 10 . Consistent with the latter notion, we found NLRX1 to be an antiviral factor and a positive regulator of early innate immune responses in human hepatocytes. HAV and HCV, both common causes of viral hepatitis in humans, are unrelated, positive-strand hepatotropic RNA viruses that share many similarities in their replication cycles and in their interactions with innate immunity 12 . Both produce dsRNA replication intermediates that induce signaling via RIG-I and TLR3 and thereby activate NF-κB and members of the IRF family, which leads to antiviral defense 12, 32 . To counter those host defenses, both HAV and HCV express proteases that target for degradation MAVS and TRIF, key adaptors in the RIG-I and TLR3 signaling pathways [33] [34] [35] [36] . Adding to those similarities, we found here that NLRX1 acted to restrict the replication of both HAV and HCV.
Surprisingly, we observed that NLRX1 had distinct, opposing effects on the SeV-induced activation of two members of the IRF family. NLXR1 was required for maximal increases in the abundance of IRF1 but suppressed the dimerization of IRF3. As key factors in inducing cytokine transcription, members of the IRF family are triggered by various stimuli in all cell types. Whereas IRF3 and IRF7 are activated by viral infection in most cell types 37, 38 , other family members, including IRF1, as well as IRF5, IRF8 and IRF9, are selectively activated by different stimuli in a cell-type-dependent manner [39] [40] [41] [42] [43] [44] . This complexity in IRF activation provides the diversity of responses required for effective host defense. However, it also allows a single regulatory molecule, such as NLRX1, to have different functional consequences when expressed in different cell types or pathogen contexts or, potentially, at different points of time in the response to an invading virus. The opposing regulatory activities of NLRX1 on early IRF3 and IRF1 responses might account for much of the controversy surrounding this protein 7, 8, 10 . We found that NLRX1 positively regulated IRF1 signaling in both BMDMs and primary MEFs. However, NLRX1 is known to attenuate innate immunological control of viral replication in these cell types [6] [7] [8] . We infer from this that IRF1 does not have a dominant role in determining the outcome of infection in these cells, at least not under the conditions tested, whereas our data showed that it did so in hepatocytes. Thus, whether NLRX1 functions as a pro-viral factor or an antiviral factor, or neither 9,31 , probably reflects which IRFs dominate in inducing antiviral responses.
Although published studies have indicated that NLRX1 negatively regulates lipopolysaccharide-and TLR4-triggered NF-κB signaling A r t i c l e s in macrophages and HEK293T human embryonic kidney cells 3,7 , we found that NLRX1 had a slight, positive effect on RIG-I-mediated NF-κB signaling in hepatocytes. However, this effect was not critical for the promotion of early cytokine responses by NLRX1, as our data showed that NLRX1 regulated the IL-6 response downstream of the influence of NF-κB.
Negative regulation of MAVS-mediated IRF3 responses by NLRX1 has been described previously 6 , but how NLRX1 affects IRF1 responses has not been studied. We found that depleting cells of NLRX1 did not alter SeV-induced transcription of IRF1 mRNA in PH5CH8 cells, but it significantly reduced the synthesis of IRF1 protein. Reductions in protein synthesis were not specific to IRF1 but instead reflected a global shutdown of protein synthesis due to enhanced activation of PKR, a phenomenon that would probably have its greatest effect on proteins that turn over rapidly, such as IRF1, which has a half-life of about 60 min.
Emerging evidence is increasingly linking translational control to the regulation of immediate responses of the innate immune system. Both IRF7 and IRF8 seem to be controlled via global, regulation of translation dependent on the translation-initiation factor eIF4E [45] [46] [47] . PKR restricts protein synthesis globally by phosphorylating eIF2α and thereby blocking the production of virus 48 . However, activation of PKR also reduces the synthesis of effector proteins encoded by interferon-stimulated genes 49 and, as we have shown here, the production of IRF1 driven by an early, NF-κB-mediated response to SeV. PKR is thus a double-edged sword, potentially weakening the cell's antiviral defenses as well as presenting a hurdle to be overcome by the virus. The negative effect of the activation of PKR on host defense might be particularly important when cells are infected with viruses such as HCV that can continue to translate their RNAs despite such activation 49 . Our data suggest that NLRX1 moderates the potentially negative consequences of PKR activation by competing with it for binding to viral RNA. This is distinct from how other members of the NLR family, including NLRP3, NLRP1 and NLRC4, physically interact with PKR to maximize activation of the inflammasome 50 .
We speculate that the opposing actions of NLRX1 on early IRF1 and IRF3 antiviral responses might underlie much of the controversy surrounding the biological function of this member of the NLR family. Loss of NLRX1 expression might result in contradictory effects on outcome of infections by different viruses in different tissues, depending on which IRF protein dominates in driving the antiviral response.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
with nuclear extracts according to the manufacturer's protocol (Odyssey Infrared EMSA kit). Electrophoresis of the resultant products was carried out with a 5% TBE gel (Bio-Rad). Native PAGE for analysis of IRF3 dimerization was performed as previously described 64 . Immunoblot analysiswas carried out using standard methods. An Odyssey Imaging System (Li-COR Biosciences) was used for visualization and signal (infrared fluorescence) intensity analysis.
Polysome profiling, [ 35 S]-metabolic labeling, and puromycin incorporation assay. Control PH5CH8 cells and PH5CH8 cells depleted of NLRX1 (2 × 10 7 ) were infected with SeV (3 × 10 4 HA units) for 2 h. Cells were then harvested, and polysome gradients were prepared and analyzed as previously described 65 . For metabolic labeling, 3 × 10 5 cells were infected with SeV (1.5 × 10 3 HA units) for 2 h and 15 min. After 15 min of starvation in methionineand cysteine-free medium, newly synthesized proteins were pulse-labeled with [ 35 S]-labeled methionine and cysteine, 125 µCi [ 35 S]/ml, for 30 min as described 66 . Protein synthesis was assessed in cells infected by SeV under similar conditions by monitoring of the incorporation of puromycin into nascent protein using a method described previously 67 . In brief, cells grown on glass slides were pulsed with puromycin (10 µg/ml) for 10 min, then were fixed with 4% paraformaldehyde, followed by staining with anti-puromycin and DAPI. Slides were imaged by laser-scanning confocal microscopy at a fixed gain in an Olympus FV1000 instrument at 40× magnification, and recorded images were analyzed with ImageJ (Fiji). Individual cells were identified by DAPI staining of nuclei, and were assigned scores for the intensity of the puromycin signal greater than an arbitrary threshold set with mock-infected control cells in each experiment. Alternatively, cells were lysed, and puromycin-labeled proteins were identified by immunoblot analysis and quantified by assessing infrared fluorescence intensity with the Odyssey Imaging System. Luciferase reporter assay. Luciferase assays, including secreted Gaussia luciferase (GLuc) analysis of HCV replication and dual luciferase assays to analyze promoter activation, were carried out as described previously 57, 68 .
ELISA. IL-6 concentrations were determined with the human IL-6 ELISA Kit (eBioscience) according to the manufacturer's protocol.
Statistical analysis.
Unless noted otherwise, all between-group comparisons were carried out by one-way or two-way ANOVA or two-sided t-test. Calculations were made using Prism 6.0 software (GraphPad Software).
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Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
Data reproducibility was confirmed in multiple independent experiments as described in legends for Figs. 1-5 and Supplementary Figs. 1-5.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Tissues for preparation of fetal human liver cells were from random donors based on availability. Age-and sex-matched wild-type and Nlrx1-/-mice were randomly allocated.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
There was no blinding in our experiments.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
